Loading
A phase 2 trial of Raludotatug deruxtecan in advanced solid tumours, run by Daiichi Sankyo, active and no longer recruiting.
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) is a phase 2 interventional study registered as NCT06660654 by Daiichi Sankyo, with 200 participants enrolled, started 2025-01-06 and due to reach its primary completion in 2027-09-30. Interventions recorded: Raludotatug deruxtecan.
Shares Raludotatug deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Raludotatug deruxtecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.